Payment overview · 2025
General Payments
$81.09
4 reported records · 2 companies
Healthcare provider profile · identity verified
Brian Harrison, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BENTON, IL · NPI 1518920073
Verified facts
What the public records show
CMS Open Payments records show Brian Harrison, MD received $81.09 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 76.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.35 | 76.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.74 | 23.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.09 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.35 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 147 |
| Lisinopril | Lisinopril | 453 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 446 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 418 | 100 |
| Gabapentin | Gabapentin | 348 | 70 |
| Montelukast Sodium | Montelukast Sodium | 334 | 82 |
| Losartan Potassium | Losartan Potassium | 317 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 314 | 55 |
| Metformin Hcl | Metformin Hcl | 285 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 65 |
| Furosemide | Furosemide | 241 | 66 |
| Meloxicam | Meloxicam | 237 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 236 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 57 |
| Omeprazole | Omeprazole | 218 | 53 |
| Alprazolam | Alprazolam | 206 | 40 |
| Potassium Chloride | Potassium Chloride | 203 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 41 |
| Buspirone Hcl | Buspirone Hcl | 171 | 32 |
| Famotidine | Famotidine | 164 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 38 |
| Simvastatin | Simvastatin | 145 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 36 |
| Trazodone Hcl | Trazodone Hcl | 116 | 29 |
| Ozempic | Semaglutide | 114 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 19 |
| Eliquis | Apixaban | 113 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 31 |
| Allopurinol | Allopurinol | 111 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 25 |
| Tramadol Hcl | Tramadol Hcl | 106 | 20 |
| Glipizide | Glipizide | 105 | 30 |
| Atenolol | Atenolol | 101 | 23 |
| Januvia | Sitagliptin Phosphate | 100 | 17 |
| Sertraline Hcl | Sertraline Hcl | 99 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 18 |
| Pregabalin | Pregabalin | 92 | 17 |
| Methylprednisolone | Methylprednisolone | 87 | 74 |
| Aripiprazole | Aripiprazole | 85 | suppressed |
| Bupropion Xl | Bupropion Hcl | 84 | 20 |
| Carvedilol | Carvedilol | 84 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 65 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 19 |
| Lovastatin | Lovastatin | 79 | 15 |
| Clonazepam | Clonazepam | 77 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | suppressed |
| Ezetimibe | Ezetimibe | 74 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 18 |
| Warfarin Sodium | Warfarin Sodium | 73 | 17 |
| Synthroid | Levothyroxine Sodium | 72 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 61 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Diazepam | Diazepam | 64 | 11 |
| Fenofibrate | Fenofibrate | 61 | 11 |
| Lorazepam | Lorazepam | 61 | 15 |
| Spironolactone | Spironolactone | 60 | 16 |
| Donepezil Hcl | Donepezil Hcl | 58 | 11 |
| Sucralfate | Sucralfate | 57 | suppressed |
| Trulicity | Dulaglutide | 56 | suppressed |
| Celecoxib | Celecoxib | 52 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 48 | suppressed |
| Nystatin | Nystatin | 47 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Metformin Hcl Er | Metformin Hcl | 44 | 11 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Torsemide | Torsemide | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 36 |
| Topiramate | Topiramate | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 28 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 13 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.09 · 4 records | ABBVIE INC. | AREXVY, SHINGRIX, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error